Liver disease associated with canalicular transport defects: Current and future therapies

Journal of Hepatology

Volumn 52, Issue 2, 2010, Pages 258-271

  Stapelbroek, Janneke M ^a,b   van Erpecum, Karel J ^b   Klomp, Leo W J ^b   Houwen, Roderick H J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Canalicular transport; Hereditary cholestasis; PFIC; Therapy

Indexed keywords

4 PHENYLBUTYRIC ACID; ABC TRANSPORTER; AMINOGLYCOSIDE; ATALUREN; BILE SALT; BILIRUBIN; CELL NUCLEUS RECEPTOR; CHAPERONE; CHOLESTEROL; COLESTYRAMINE; CONSTITUTIVE ANDROSTANE RECEPTOR; FARNESOID X RECEPTOR; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; HEAT SHOCK PROTEIN; MULTIDRUG RESISTANCE PROTEIN 3; ORGANIC ANION TRANSPORTER; PHENOBARBITAL; PHOSPHATIDYLCHOLINE; PREGNANE X RECEPTOR; PROTEIN; PROTEIN BSEP; PROTEIN FIC1; PROTEIN FIC2; RIFAMPICIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ABCB4 GENE; ABCC2 GENE; ABCG5 GENE; ABCG8 GENE; ALBUMIN DIALYSIS; ATP8B1 GENE; BENIGN RECURRENT INTRAHEPATIC CHOLESTASIS; BILE; BILE FLOW; BILE SECRETION; BILIARY TRACT DRAINAGE; CHOLESTASIS; CLINICAL PRACTICE; CONSTIPATION; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG TARGETING; DUBIN JOHNSON SYNDROME; GENE; GENE MUTATION; HUMAN; ILEUM BYPASS; INTRAHEPATIC BILE DUCT; INTRAHEPATIC CHOLESTASIS; LIVER DISEASE; LIVER TRANSPLANTATION; METABOLIC DISORDER; MISSENSE MUTATION; NONHUMAN; PARTIAL BILIARY DIVERSION; PARTIAL EXTERNAL BILIARY DIVERSION; PRIORITY JOURNAL; PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS; PROTEIN EXPRESSION; PRURITUS; REVIEW; SCLEROSING CHOLANGITIS; SITOSTEROLEMIA; STOP CODON; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; ATP-BINDING CASSETTE TRANSPORTERS; BILE; BILE CANALICULI; BILIARY TRACT SURGICAL PROCEDURES; BIOLOGICAL TRANSPORT, ACTIVE; CHOLESTYRAMINE RESIN; GENE THERAPY; HUMANS; LIPOPROTEINS; LIVER DISEASES; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MUTATION; P-GLYCOPROTEINS; RIFAMPIN; URSODEOXYCHOLIC ACID;

EID: 75349107079     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2009.11.012     Document Type: Review

References (211)

1. Oldham M.L., Davidson A.L., and Chen J. Structural insights into ABC transporter mechanism. Curr Opin Struct Biol 18 (2008) 726-733
2. Borst P., and Elferink R.O. Mammalian ABC transporters in health and disease. Annu Rev Biochem 71 (2002) 537-592
3. Bull L.N., van Eijk M.J., Pawlikowska L., DeYoung J.A., Juijn J.A., Liao M., et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet 18 (1998) 219-224
4. Paulusma C.C., Folmer D.E., Ho-Mok K.S., de Waart D.R., Hilarius P.M., Verhoeven A.J., et al. ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 47 (2008) 268-278
5. Pomorski T., Lombardi R., Riezman H., Devaux P.F., van M.G., and Holthuis J.C. Drs2p-related P-type ATPases Dnf1p and Dnf2p are required for phospholipid translocation across the yeast plasma membrane and serve a role in endocytosis. Mol Biol Cell 14 (2003) 1240-1254
6. Ujhazy P., Ortiz D., Misra S., Li S., Moseley J., Jones H., et al. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 34 (2001) 768-775
7. Cai S.Y., Gautam S., Nguyen T., Soroka C.J., Rahner C., and Boyer J.L. ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 136 (2009) 1060-1069
8. Amigo L., Mendoza H., Zanlungo S., Miquel J.F., Rigotti A., Gonzalez S., et al. Enrichment of canalicular membrane with cholesterol and sphingomyelin prevents bile salt-induced hepatic damage. J Lipid Res 40 (1999) 533-542
9. Paulusma C.C., Groen A., Kunne C., Ho-Mok K.S., Spijkerboer A.L., Rudi de W.D., et al. Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 44 (2006) 195-204
10. Paulusma C.C., Dewaart D.R., Kunne C., Mok K.S., and Oude Elferink R.P. Activity of the bile salt export pump (ABCB11) is critically dependent on canalicular membrane cholesterol content. J Biol Chem (2009)
11. Ismair M.G., Hausler S., Stuermer C.A., Guyot C., Meier P.J., Roth J., et al. ABC-transporters are localized in caveolin-1-positive and reggie-1-negative and reggie-2-negative microdomains of the canalicular membrane in rat hepatocytes. Hepatology 49 (2009) 1673-1682
12. Bull L.N., Carlton V.E., Stricker N.L., Baharloo S., DeYoung J.A., Freimer N.B., et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Byler disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology 26 (1997) 155-164
13. Groen A., Kunne C., Jongsma G., van den O.K., Mok K.S., Petruzzelli M., et al. Abcg5/8 independent biliary cholesterol excretion in Atp8b1-deficient mice. Gastroenterology 134 (2008) 2091-2100
14. Klomp L.W., Vargas J.C., van Mil S.W., Pawlikowska L., Strautnieks S.S., van Eijk M.J., et al. Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology 40 (2004) 27-38
15. Klomp L.W., Bull L.N., Knisely A.S., van Der Doelen M.A., Juijn J.A., Berger R., et al. A missense mutation in FIC1 is associated with Greenland familial cholestasis. Hepatology 32 (2000) 1337-1341
16. Bourke B., Goggin N., Walsh D., Kennedy S., Setchell K.D., and Drumm B. Byler-like familial cholestasis in an extended kindred. Arch Dis Child 75 (1996) 223-227
17. Clayton R.J., Iber F.L., Ruebner B.H., and McKusick V.A. Byler disease. Fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child 117 (1969) 112-124
18. Nielsen I.M., Ornvold K., Jacobsen B.B., and Ranek L. Fatal familial cholestatic syndrome in Greenland Eskimo children. Acta Paediatr Scand 75 (1986) 1010-1016
19. Brenard R., Geubel A.P., and Benhamou J.P. Benign recurrent intrahepatic cholestasis. A report of 26 cases. J Clin Gastroenterol 11 (1989) 546-551
20. De Koning T.J., Sandkuijl L.A., De Schryver J.E., Hennekam E.A., Beemer F.A., and Houwen R.H. Autosomal-recessive inheritance of benign recurrent intrahepatic cholestasis. Am J Med Genet 57 (1995) 479-482
21. Summerskill W.H., and Walshe J.M. Benign recurrent intrahepatic "obstructive" jaundice. Lancet 2 (1959) 686-690
22. Tygstrup N., Steig B.A., Juijn J.A., Bull L.N., and Houwen R.H. Recurrent familial intrahepatic cholestasis in the Faeroe Islands. Phenotypic heterogeneity but genetic homogeneity. Hepatology 29 (1999) 506-508
23. van Mil S.W., Klomp L.W., Bull L.N., and Houwen R.H. FIC1 disease: a spectrum of intrahepatic cholestatic disorders. Semin Liver Dis 21 (2001) 535-544
24. van Ooteghem N.A., Klomp L.W., van Berge-Henegouwen G.P., and Houwen R.H. Benign recurrent intrahepatic cholestasis progressing to progressive familial intrahepatic cholestasis: low GGT cholestasis is a clinical continuum. J Hepatol 36 (2002) 439-443
25. Knisely A.S. Progressive familial intrahepatic cholestasis: a personal perspective. Pediatr Dev Pathol 3 (2000) 113-125
26. Eppens E.F., van Mil S.W., De Vree J.M., Mok K.S., Juijn J.A., Oude Elferink R.P., et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol 35 (2001) 436-443
27. van Mil S.W., van Oort M.M., van dB I., Berger R., Houwen R.H., and Klomp L.W. Fic1 is expressed at apical membranes of different epithelial cells in the digestive tract and is induced in the small intestine during postnatal development of mice. Pediatr Res 56 (2004) 981-987
28. Harris M.J., and Arias I.M. FIC1, a P-type ATPase linked to cholestatic liver disease, has homologues (ATP8B2 and ATP8B3) expressed throughout the body. Biochim Biophys Acta 1633 (2003) 127-131
29. Stapelbroek J.M., Peters T.A., van Beurden D.H., Curfs J.H., Joosten A., Beynon A.J., et al. ATP8B1 is essential for maintaining normal hearing. Proc Natl Acad Sci USA (2009)
30. Chen H.L., Chang P.S., Hsu H.C., Ni Y.H., Hsu H.Y., Lee J.H., et al. FIC1 and BSEP defects in Taiwanese patients with chronic intrahepatic cholestasis with low gamma-glutamyltranspeptidase levels. J Pediatr 140 (2002) 119-124
31. Lykavieris P., van M.S., Cresteil D., Fabre M., Hadchouel M., Klomp L., et al. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J Hepatol 39 (2003) 447-452
32. Knisely A.S., Agostini R.M., Zitelli B.J., Kocoshis S.A., and Boyle J.T. Byler's syndrome. Arch Dis Child 77 (1997) 276-277
33. Oshima T., Ikeda K., and Takasaka T. Sensorineural hearing loss associated with Byler disease. Tohoku J Exp Med 187 (1999) 83-88
34. Mullenbach R., Bennett A., Tetlow N., Patel N., Hamilton G., Cheng F., et al. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 54 (2005) 829-834
35. Painter J.N., Savander M., Ropponen A., Nupponen N., Riikonen S., Ylikorkala O., et al. Sequence variation in the ATP8B1 gene and intrahepatic cholestasis of pregnancy. Eur J Hum Genet 13 (2005) 435-439
36. Strautnieks S.S., Bull L.N., Knisely A.S., Kocoshis S.A., Dahl N., Arnell H., et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet 20 (1998) 233-238
37. Strautnieks S.S., Byrne J.A., Pawlikowska L., Cebecauerova D., Rayner A., Dutton L., et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology 134 (2008) 1203-1214
38. Jansen P.L., Strautnieks S.S., Jacquemin E., Hadchouel M., Sokal E.M., Hooiveld G.J., et al. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117 (1999) 1370-1379
39. Lam C.W., Cheung K.M., Tsui M.S., Yan M.S., Lee C.Y., and Tong S.F. A patient with novel ABCB11 gene mutations with phenotypic transition between BRIC2 and PFIC2. J Hepatol 44 (2006) 240-242
40. Takahashi A., Hasegawa M., Sumazaki R., Suzuki M., Toki F., Suehiro T., et al. Gradual improvement of liver function after administration of ursodeoxycholic acid in an infant with a novel ABCB11 gene mutation with phenotypic continuum between BRIC2 and PFIC2. Eur J Gastroenterol Hepatol 19 (2007) 942-946
41. van Mil S.W., van der Woerd W.L., van der B.G., Sturm E., Jansen P.L., Bull L.N., et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology 127 (2004) 379-384
42. Thompson R., and Strautnieks S. BSEP: function and role in progressive familial intrahepatic cholestasis. Semin Liver Dis 21 (2001) 545-550
43. Gerloff T., Stieger B., Hagenbuch B., Madon J., Landmann L., Roth J., et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem 273 (1998) 10046-10050
44. Keitel V., Burdelski M., Warskulat U., Kuhlkamp T., Keppler D., Haussinger D., et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology 41 (2005) 1160-1172
45. Knisely A.S., Strautnieks S.S., Meier Y., Stieger B., Byrne J.A., Portmann B.C., et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology 44 (2006) 478-486
46. Scheimann A.O., Strautnieks S.S., Knisely A.S., Byrne J.A., Thompson R.J., and Finegold M.J. Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma. J Pediatr 150 (2007) 556-559
47. Lang C., Meier Y., Stieger B., Beuers U., Lang T., Kerb R., et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 17 (2007) 47-60
48. Dixon P.H., van Mil S.W., Chambers J., Strautnieks S., Thompson R.J., Lammert F., et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut 58 (2009) 537-544
49. Meier Y., Zodan T., Lang C., Zimmermann R., Kullak-Ublick G.A., Meier P.J., et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 14 (2008) 38-45
50. Pauli-Magnus C., Lang T., Meier Y., Zodan-Marin T., Jung D., Breymann C., et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 14 (2004) 91-102
51. Hermeziu B., Sanlaville D., Girard M., Leonard C., Lyonnet S., and Jacquemin E. Heterozygous bile salt export pump deficiency: a possible genetic predisposition to transient neonatal cholestasis. J Pediatr Gastroenterol Nutr 42 (2006) 114-116
52. Smit J.J., Schinkel A.H., Mol C.A., Majoor D., Mooi W.J., Jongsma A.P., et al. Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest 71 (1994) 638-649
53. Smith A.J., Timmermans-Hereijgers J.L., Roelofsen B., Wirtz K.W., van Blitterswijk W.J., Smit J.J., et al. The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett 354 (1994) 263-266
54. van Helvoort A., Smith A.J., Sprong H., Fritzsche I., Schinkel A.H., Borst P., et al. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87 (1996) 507-517
55. De Vree J.M., Jacquemin E., Sturm E., Cresteil D., Bosma P.J., Aten J., et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc Natl Acad Sci USA 95 (1998) 282-287
56. Degiorgio D., Colombo C., Seia M., Porcaro L., Costantino L., Zazzeron L., et al. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur J Hum Genet 15 (2007) 1230-1238
57. Gotthardt D., Runz H., Keitel V., Fischer C., Flechtenmacher C., Wirtenberger M., et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. Hepatology 48 (2008) 1157-1166
58. Ziol M., Barbu V., Rosmorduc O., Frassati-Biaggi A., Barget N., Hermelin B., et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology 135 (2008) 131-141
59. Dixon P.H., Weerasekera N., Linton K.J., Donaldson O., Chambers J., Egginton E., et al. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum Mol Genet 9 (2000) 1209-1217
60. Schneider G., Paus T.C., Kullak-Ublick G.A., Meier P.J., Wienker T.F., Lang T., et al. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology 45 (2007) 150-158
61. Floreani A., Carderi I., Paternoster D., Soardo G., Azzaroli F., Esposito W., et al. Intrahepatic cholestasis of pregnancy: three novel MDR3 gene mutations. Aliment Pharmacol Ther 23 (2006) 1649-1653
62. Floreani A., Carderi I., Paternoster D., Soardo G., Azzaroli F., Esposito W., et al. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. Dig Liver Dis 40 (2008) 366-370
63. Gendrot C., Bacq Y., Brechot M.C., Lansac J., and Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J Med Genet 40 (2003) e32
64. Jacquemin E., Cresteil D., Manouvrier S., Boute O., and Hadchouel M. Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet 353 (1999) 210-211
65. Mullenbach R., Linton K.J., Wiltshire S., Weerasekera N., Chambers J., Elias E., et al. ABCB4 gene sequence variation in women with intrahepatic cholestasis of pregnancy. J Med Genet 40 (2003) e70
66. Wasmuth H.E., Glantz A., Keppeler H., Simon E., Bartz C., Rath W., et al. Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene. Gut 56 (2007) 265-270
67. Jung C., Driancourt C., Baussan C., Zater M., Hadchouel M., Meunier-Rotival M., et al. Prenatal molecular diagnosis of inherited cholestatic diseases. J Pediatr Gastroenterol Nutr 44 (2007) 453-458
68. Nakken K.E., Labori K.J., Rodningen O.K., Nakken S., Berge K.E., Eiklid K., et al. ABCB4 sequence variations in young adults with cholesterol gallstone disease. Liver Int 29 (2009) 743-747
69. Rosmorduc O., Hermelin B., and Poupon R. MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology 120 (2001) 1459-1467
70. Rosmorduc O., Hermelin B., Boelle P.Y., Parc R., Taboury J., and Poupon R. ABCB4 gene mutation-associated cholelithiasis in adults. Gastroenterology 125 (2003) 452-459
71. Rosmorduc O., and Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis 2 (2007) 29
72. Lucena J.F., Herrero J.I., Quiroga J., Sangro B., Garcia-Foncillas J., Zabalegui N., et al. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124 (2003) 1037-1042
73. Sandusky G.E., Mintze K.S., Pratt S.E., and Dantzig A.H. Expression of multidrug resistance-associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays. Histopathology 41 (2002) 65-74
74. Schaub T.P., Kartenbeck J., Konig J., Spring H., Dorsam J., Staehler G., et al. Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J Am Soc Nephrol 10 (1999) 1159-1169
75. Kamisako T., Leier I., Cui Y., Konig J., Buchholz U., Hummel-Eisenbeiss J., et al. Transport of monoglucuronosyl and bisglucuronosyl bilirubin by recombinant human and rat multidrug resistance protein 2. Hepatology 30 (1999) 485-490
76. Akita H., Suzuki H., Ito K., Kinoshita S., Sato N., Takikawa H., et al. Characterization of bile acid transport mediated by multidrug resistance associated protein 2 and bile salt export pump. Biochim Biophys Acta 1511 (2001) 7-16
77. Corpechot C., Ping C., Wendum D., Matsuda F., Barbu V., and Poupon R. Identification of a novel 974C → G nonsense mutation of the MRP2/ABCC2 gene in a patient with Dubin-Johnson syndrome and analysis of the effects of rifampicin and ursodeoxycholic acid on serum bilirubin and bile acids. Am J Gastroenterol 101 (2006) 2427-2432
78. Dubin I.N., and Johnson F.B. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 33 (1954) 155-197
79. Rastogi A., Krishnani N., and Pandey R. Dubin-Johnson syndrome - a clinicopathologic study of twenty cases. Indian J Pathol Microbiol 49 (2006) 500-504
80. Nies A.T., and Keppler D. The apical conjugate efflux pump ABCC2 (MRP2). Pflugers Arch 453 (2007) 643-659
81. Klett E.L., Lee M.H., Adams D.B., Chavin K.D., and Patel S.B. Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine. BMC Gastroenterol 4 (2004) 21
82. Graf G.A., Li W.P., Gerard R.D., Gelissen I., White A., Cohen J.C., et al. Coexpression of ATP-binding cassette proteins ABCG5 and ABCG8 permits their transport to the apical surface. J Clin Invest 110 (2002) 659-669
83. Graf G.A., Yu L., Li W.P., Gerard R., Tuma P.L., Cohen J.C., et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem 278 (2003) 48275-48282
84. Berge K.E., Tian H., Graf G.A., Yu L., Grishin N.V., Schultz J., et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 290 (2000) 1771-1775
85. Lee M.H., Lu K., Hazard S., Yu H., Shulenin S., Hidaka H., et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 27 (2001) 79-83
86. Lam C.W., Cheng A.W., Tong S.F., and Chan Y.W. Novel donor splice site mutation of ABCG5 gene in sitosterolemia. Mol Genet Metab 75 (2002) 178-180
87. Heimerl S., Langmann T., Moehle C., Mauerer R., Dean M., Beil F.U., et al. Mutations in the human ATP-binding cassette transporters ABCG5 and ABCG8 in sitosterolemia. Hum Mutat 20 (2002) 151
88. Alam M., Garzon M.C., Salen G., and Starc T.J. Tuberous xanthomas in sitosterolemia. Pediatr Dermatol 17 (2000) 447-449
89. Katayama T., Satoh T., Yagi T., Hirose N., Kurita Y., Anzai T., et al. A 19-year-old man with myocardial infarction and sitosterolemia. Intern Med 42 (2003) 591-594
90. Kolovou G., Voudris V., Drogari E., Palatianos G., and Cokkinos D.V. Coronary bypass grafts in a young girl with sitosterolemia. Eur Heart J 17 (1996) 965-966
91. Rees D.C., Iolascon A., Carella M., O'marcaigh A.S., Kendra J.R., Jowitt S.N., et al. Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean stomatocytosis/macrothrombocytopenia) is the haematological presentation of phytosterolaemia. Br J Haematol 130 (2005) 297-309
92. Miettinen T.A., Klett E.L., Gylling H., Isoniemi H., and Patel S.B. Liver transplantation in a patient with sitosterolemia and cirrhosis. Gastroenterology 130 (2006) 542-547
93. Hidaka H., Nakamura T., Aoki T., Kojima H., Nakajima Y., Kosugi K., et al. Increased plasma plant sterol levels in heterozygotes with sitosterolemia and xanthomatosis. J Lipid Res 31 (1990) 881-888
94. Lazaridis K.N., Gores G.J., and Lindor K.D. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J Hepatol 35 (2001) 134-146
95. Paumgartner G., and Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36 (2002) 525-531
96. Beuers U., Bilzer M., Chittattu A., Kullak-Ublick G.A., Keppler D., Paumgartner G., et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. Hepatology 33 (2001) 1206-1216
97. Dumont M., Emmanuel J., and Serge E. Effect of ursodeoxycholic acid on the expression of the hepatocellular bile acid transporters (Ntcp and bsep) in rats with estrogen-induced cholestasis. J Pediatr Gastroenterol Nutr 35 (2002) 185-191
98. Fickert P., Zollner G., Fuchsbichler A., Stumptner C., Pojer C., Zenz R., et al. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. Gastroenterology 121 (2001) 170-183
99. Marschall H.U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 129 (2005) 476-485
100. Hofmann A.F., Zakko S.F., Lira M., Clerici C., Hagey L.R., Lambert K.K., et al. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. Hepatology 42 (2005) 1391-1398
101. van de Meeberg P.C., van Erpecum K.J., and van Berge-Henegouwen G.P. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol Suppl 200 (1993) 15-20
102. Jacquemin E., Hermans D., Myara A., Habes D., Debray D., Hadchouel M., et al. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25 (1997) 519-523
103. Jacquemin E., De Vree J.M., Cresteil D., Sokal E.M., Sturm E., Dumont M., et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology 120 (2001) 1448-1458
104. Wanty C., Joomye R., Van H.N., Paul K., Otte J.B., Reding R., et al. Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol Belg 67 (2004) 313-319
105. Morton D.H., Salen G., Batta A.K., Shefer S., Tint G.S., Belchis D., et al. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 119 (2000) 188-195
106. Ismail H., Kalicinski P., Markiewicz M., Jankowska I., Pawlowska J., Kluge P., et al. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr Transplant 3 (1999) 219-224
107. Naveh Y., Bassan L., Rosenthal E., Berkowitz D., Jaffe M., Mandel H., et al. Progressive familial intrahepatic cholestasis among the Arab population in Israel. J Pediatr Gastroenterol Nutr 24 (1997) 548-554
108. Whitington P.F., Freese D.K., Alonso E.M., Schwarzenberg S.J., and Sharp H.L. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 18 (1994) 134-141
109. Bustorff-Silva J., Sbraggia N.L., Olimpio H., de Alcantara R.V., Matsushima E., De Tommaso A.M., et al. Partial internal biliary diversion through a cholecystojejunocolonic anastomosis - a novel surgical approach for patients with progressive familial intrahepatic cholestasis: a preliminary report. J Pediatr Surg 42 (2007) 1337-1340
110. Emerick K.M., Elias M.S., Melin-Aldana H., Strautnieks S., Thompson R.J., Bull L.N., et al. Bile composition in alagille syndrome and PFIC patients having partial external biliary diversion. BMC Gastroenterol 8 (2008) 47
111. Englert C., Grabhorn E., Richter A., Rogiers X., Burdelski M., and Ganschow R. Liver transplantation in children with progressive familial intrahepatic cholestasis. Transplantation 84 (2007) 1361-1363
112. Kurbegov A.C., Setchell K.D., Haas J.E., Mierau G.W., Narkewicz M., Bancroft J.D., et al. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 125 (2003) 1227-1234
113. Yerushalmi B., Sokol R.J., Narkewicz M.R., Smith D., and Karrer F.M. Use of rifampin for severe pruritus in children with chronic cholestasis. J Pediatr Gastroenterol Nutr 29 (1999) 442-447
114. Crosignani A., Podda M., Bertolini E., Battezzati P.M., Zuin M., and Setchell K.D. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology 13 (1991) 1076-1083
115. Cancado E.L., Leitao R.M., Carrilho F.J., and Laudanna A.A. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am J Gastroenterol 93 (1998) 1510-1517
116. Metzelder M.L., Petersen C., Melter M., and Ure B.M. Modified laparoscopic external biliary diversion for benign recurrent intrahepatic cholestasis in obese adolescents. Pediatr Surg Int 22 (2006) 551-553
117. Regev R.H., Stolar O., Raz A., and Dolfin T. Treatment of severe cholestasis in neonatal Dubin-Johnson syndrome with ursodeoxycholic acid. J Perinat Med 30 (2002) 185-187
118. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130 (2006) 465-481
119. Wietholtz H., Marschall H.U., Sjovall J., and Matern S. Stimulation of bile acid 6 alpha-hydroxylation by rifampin. J Hepatol 24 (1996) 713-718
120. Balsells F., Wyllie R., Steffen R., and Kay M. Benign recurrent intrahepatic cholestasis: improvement of pruritus and shortening of the symptomatic phase with rifampin therapy: a case report. Clin Pediatr (Phila) 36 (1997) 483-485
121. Garbutt J.T., and Kenney T.J. Effect of cholestyramine on bile acid metabolism in normal man. J Clin Invest 51 (1972) 2781-2789
122. Nakagawa M., Tazawa Y., Kobayashi Y., Yamada M., Suzuki H., Konno T., et al. Familial intrahepatic cholestasis associated with progressive neuromuscular disease and vitamin E deficiency. J Pediatr Gastroenterol Nutr 3 (1984) 385-389
123. Whitington P.F., and Whitington G.L. Partial external diversion of bile for the treatment of intractable pruritus associated with intrahepatic cholestasis. Gastroenterology 95 (1988) 130-136
124. Uegaki S., Tanaka A., Mori Y., Kodama H., Fukusato T., and Takikawa H. Successful treatment with colestimide for a bout of cholestasis in a Japanese patient with benign recurrent intrahepatic cholestasis caused by ATP8B1 mutation. Intern Med 47 (2008) 599-602
125. Al Drees K., Al Z.A., Al A.A., and Abdulla A. Benign recurrent intrahepatic cholestasis in a Saudi child. Ann Trop Paediatr 19 (1999) 215-217
126. Odievre M., Gautier M., Hadchouel M., and Alagille D. Severe familial intrahepatic cholestasis. Arch Dis Child 48 (1973) 806-812
127. Bays H.E., and Goldberg R.B. The 'forgotten' bile acid sequestrants: is now a good time to remember?. Am J Ther 14 (2007) 567-580
128. Belamarich P.F., Deckelbaum R.J., Starc T.J., Dobrin B.E., Tint G.S., and Salen G. Response to diet and cholestyramine in a patient with sitosterolemia. Pediatrics 86 (1990) 977-981
129. Nguyen L.B., Cobb M., Shefer S., Salen G., Ness G.C., and Tint G.S. Regulation of cholesterol biosynthesis in sitosterolemia: effects of lovastatin, cholestyramine, and dietary sterol restriction. J Lipid Res 32 (1991) 1941-1948
130. Gregg R.E., Connor W.E., Lin D.S., and Brewer Jr. H.B. Abnormal metabolism of shellfish sterols in a patient with sitosterolemia and xanthomatosis. J Clin Invest 77 (1986) 1864-1872
131. Salen G., Kwiterovich Jr. P.O., Shefer S., Tint G.S., Horak I., Shore V., et al. Increased plasma cholestanol and 5 alpha-saturated plant sterol derivatives in subjects with sitosterolemia and xanthomatosis. J Lipid Res 26 (1985) 203-209
132. Cobb M.M., Salen G., Tint G.S., Greenspan J., and Nguyen L.B. Sitosterolemia: opposing effects of cholestyramine and lovastatin on plasma sterol levels in a homozygous girl and her heterozygous father. Metabolism 45 (1996) 673-679
133. Saich R., Collins P., Ala A., Standish R., and Hodgson H. Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis. Eur J Gastroenterol Hepatol 17 (2005) 585-588
134. Sturm E., Franssen C.F., Gouw A., Staels B., Boverhof R., De Knegt R.J., et al. Extracorporal albumin dialysis (MARS) improves cholestasis and normalizes low apo A-I levels in a patient with benign recurrent intrahepatic cholestasis (BRIC). Liver 22 (2002) 72-75
135. Hollands C.M., Rivera-Pedrogo F.J., Gonzalez-Vallina R., Loret-de-Mola O., Nahmad M., and Burnweit C.A. Ileal exclusion for Byler's disease: an alternative surgical approach with promising early results for pruritus. J Pediatr Surg 33 (1998) 220-224
136. Ekinci S., Karnak I., Gurakan F., Yuce A., Senocak M.E., Cahit T.F., et al. Partial external biliary diversion for the treatment of intractable pruritus in children with progressive familial intrahepatic cholestasis: report of two cases. Surg Today 38 (2008) 726-730
137. Emond J.C., and Whitington P.F. Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). J Pediatr Surg 30 (1995) 1635-1641
138. Melter M., Rodeck B., Kardorff R., Hoyer P.F., Petersen C., Ballauff A., et al. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am J Gastroenterol 95 (2000) 3522-3528
139. Ng V.L., Ryckman F.C., Porta G., Miura I.K., de C.E., Servidoni M.F., et al. Long-term outcome after partial external biliary diversion for intractable pruritus in patients with intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 30 (2000) 152-156
140. Rebhandl W., Felberbauer F.X., Turnbull J., Paya K., Barcik U., Huber W.D., et al. Biliary diversion by use of the appendix (cholecystoappendicostomy) in progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 28 (1999) 217-219
141. Arnell H., Bergdahl S., Papadogiannakis N., Nemeth A., and Fischler B. Preoperative observations and short-term outcome after partial external biliary diversion in 13 patients with progressive familial intrahepatic cholestasis. J Pediatr Surg 43 (2008) 1312-1320
142. Metzelder M.L., Bottlander M., Melter M., Petersen C., and Ure B.M. Laparoscopic partial external biliary diversion procedure in progressive familial intrahepatic cholestasis: a new approach. Surg Endosc 19 (2005) 1641-1643
143. Yang H., Porte R.J., Verkade H.J., De Langen Z.J., and Hulscher J.B. Partial external biliary diversion in children with progressive familial intrahepatic cholestasis and alagille disease. J Pediatr Gastroenterol Nutr (2009)
144. Kalicinski P.J., Ismail H., Jankowska I., Kaminski A., Pawlowska J., Drewniak T., et al. Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur J Pediatr Surg 13 (2003) 307-311
145. Stapelbroek J.M., van Erpecum K.J., Klomp L.W., Venneman N.G., Schwartz T.P., van Berge-Henegouwen G.P., et al. Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology 43 (2006) 51-53
146. Soubrane O., Gauthier F., Devictor D., Bernard O., Valayer J., Houssin D., et al. Orthotopic liver transplantation for Byler disease. Transplantation 50 (1990) 804-806
147. Aydogdu S., Cakir M., Arikan C., Tumgor G., Yuksekkaya H.A., Yilmaz F., et al. Liver transplantation for progressive familial intrahepatic cholestasis: clinical and histopathological findings, outcome and impact on growth. Pediatr Transplant 11 (2007) 634-640
148. Bassas A., Chehab M., Hebby H., Al S.M., Al H.H., Al Z.A., et al. Living related liver transplantation in 13 cases of progressive familial intrahepatic cholestasis. Transplant Proc 35 (2003) 3003-3005
149. Cutillo L., Najimi M., Smets F., Janssen M., Reding R., de Ville de G.J., et al. Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis. Pediatr Transplant 10 (2006) 570-574
150. Egawa H., Yorifuji T., Sumazaki R., Kimura A., Hasegawa M., and Tanaka K. Intractable diarrhea after liver transplantation for Byler's disease: successful treatment with bile adsorptive resin. Liver Transpl 8 (2002) 714-716
151. Khan I., Al-Shaqrani M.A., Arain Z.B., Al-Hebbi H.A., Wali S.H., and Bassas A.F. One hundred and thirty-seven living donor pediatric liver transplants at Riyadh Military Hospital. Results and outlook for future. Saudi Med J 30 (2009) 403-408
152. D'Antiga L., Moniz C., Buxton-Thomas M., Cheeseman P., Gray B., Abraha H., et al. Bone mineral density and height gain in children with chronic cholestatic liver disease undergoing transplantation. Transplantation 73 (2002) 1788-1793
153. Usui M., Isaji S., Das B.C., Kobayashi M., Osawa I., Iida T., et al. Liver retransplantation with external biliary diversion for progressive familial intrahepatic cholestasis type 1: a case report. Pediatr Transplant (2008)
154. Miyagawa-Hayashino A., Egawa H., Yorifuji T., Hasegawa M., Haga H., Tsuruyama T., et al. Allograft steatohepatitis in progressive familial intrahepatic cholestasis type 1 after living donor liver transplantation. Liver Transpl 15 (2009) 610-618
155. Davit-Spraul A., Gonzales E., Baussan C., and Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 4 (2009) 1
156. De Vree J.M., Ottenhoff R., Bosma P.J., Smith A.J., Aten J., and Oude Elferink R.P. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119 (2000) 1720-1730
157. Quaglia A., Lehec S.C., Hughes R.D., Mitry R.R., Knisely A.S., Devereaux S., et al. Liver after hepatocyte transplantation for liver-based metabolic disorders in children. Cell Transplant 17 (2008) 1403-1414
158. Dhawan A., Mitry R.R., and Hughes R.D. Hepatocyte transplantation for liver-based metabolic disorders. J Inherit Metab Dis 29 (2006) 431-435
159. Eloranta J.J., Meier P.J., and Kullak-Ublick G.A. Coordinate transcriptional regulation of transport and metabolism. Methods Enzymol 400 (2005) 511-530
160. Huang L., Zhao A., Lew J.L., Zhang T., Hrywna Y., Thompson J.R., et al. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J Biol Chem 278 (2003) 51085-51090
161. Kast H.R., Goodwin B., Tarr P.T., Jones S.A., Anisfeld A.M., Stoltz C.M., et al. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 277 (2002) 2908-2915
162. Plass J.R., Mol O., Heegsma J., Geuken M., Faber K.N., Jansen P.L., et al. Farnesoid X receptor and bile salts are involved in transcriptional regulation of the gene encoding the human bile salt export pump. Hepatology 35 (2002) 589-596
163. Zollner G., and Trauner M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br J Pharmacol 156 (2009) 7-27
164. Fiorucci S., Clerici C., Antonelli E., Orlandi S., Goodwin B., Sadeghpour B.M., et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther 313 (2005) 604-612
165. Mottino A.D., Cao J., Veggi L.M., Crocenzi F., Roma M.G., and Vore M. Altered localization and activity of canalicular Mrp2 in estradiol-17beta-d-glucuronide-induced cholestasis. Hepatology 35 (2002) 1409-1419
166. Stieger B., Fattinger K., Madon J., Kullak-Ublick G.A., and Meier P.J. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118 (2000) 422-430
167. Demeilliers C., Jacquemin E., Barbu V., Mergey M., Paye F., Fouassier L., et al. Altered hepatobiliary gene expressions in PFIC1: ATP8B1 gene defect is associated with CFTR downregulation. Hepatology 43 (2006) 1125-1134
168. Pawlikowska L., Groen A., Eppens E.F., Kunne C., Ottenhoff R., Looije N., et al. A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum Mol Genet 13 (2004) 881-892
169. Alvarez L., Jara P., Sanchez-Sabate E., Hierro L., Larrauri J., Diaz M.C., et al. Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 13 (2004) 2451-2460
170. Chen F., Ananthanarayanan M., Emre S., Neimark E., Bull L.N., Knisely A.S., et al. Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126 (2004) 756-764
171. Frankenberg T., Miloh T., Chen F.Y., Ananthanarayanan M., Sun A.Q., Balasubramaniyan N., et al. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48 (2008) 1896-1905
172. Koh S., Takada T., Kukuu I., and Suzuki H. FIC1-mediated stimulation of FXR activity is decreased with PFIC1 mutations in HepG2 cells. J Gastroenterol (2009)
173. Martinez-Fernandez P., Hierro L., Jara P., and Alvarez L. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064. Am J Physiol Gastrointest Liver Physiol 296 (2009) G1119-G1129
174. Shoda J., Okada K., Inada Y., Kusama H., Utsunomiya H., Oda K., et al. Bezafibrate induces multidrug-resistance P-Glycoprotein 3 expression in cultured human hepatocytes and humanized livers of chimeric mice. Hepatol Res 37 (2007) 548-556
175. Chianale J., Vollrath V., Wielandt A.M., Amigo L., Rigotti A., Nervi F., et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 314 (1996) 781-786
176. Kurihara T., Niimi A., Maeda A., Shigemoto M., and Yamashita K. Study of effectiveness of bezafibrate in the treatment of chronic hepatitis C. Am J Gastroenterol 96 (2001) 1659-1660
177. Kurihara T., Maeda A., Shigemoto M., Yamashita K., and Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy. Am J Gastroenterol 97 (2002) 212-214
178. Kurihara T., Maeda A., Shigemoto M., Yamashita K., and Kamatani N. Efficacy of bezafibrate in a patient with primary sclerosing cholangitis. J Gastroenterol 38 (2003) 300-301
179. Kurihara T., Niimi A., Maeda A., Shigemoto M., and Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol 95 (2000) 2990-2992
180. Hacein-Bey-Abina S., Von K.C., Schmidt M., Le D.F., Wulffraat N., McIntyre E., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 (2003) 255-256
181. Luzzatto L., Apirion D., and Schlessinger D. Mechanism of action of streptomycin in E. coli: interruption of the ribosome cycle at the initiation of protein synthesis. Proc Natl Acad Sci USA 60 (1968) 873-880
182. Ruusala T., and Kurland C.G. Streptomycin preferentially perturbs ribosomal proofreading. Mol Gen Genet 198 (1984) 100-104
183. Clancy J.P., Bebok Z., Ruiz F., King C., Jones J., Walker L., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 163 (2001) 1683-1692
184. Wilschanski M., Yahav Y., Yaacov Y., Blau H., Bentur L., Rivlin J., et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 349 (2003) 1433-1441
185. Welch E.M., Barton E.R., Zhuo J., Tomizawa Y., Friesen W.J., Trifillis P., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
186. Hirawat S., Welch E.M., Elfring G.L., Northcutt V.J., Paushkin S., Hwang S., et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47 (2007) 430-444
187. Kerem E., Hirawat S., Armoni S., Yaakov Y., Shoseyov D., Cohen M., et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372 (2008) 719-727
188. Welch W.J. Role of quality control pathways in human diseases involving protein misfolding. Semin Cell Dev Biol 15 (2004) 31-38
189. Dover G.J., Brusilow S., and Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 327 (1992) 569-570
190. Maestri N.E., Brusilow S.W., Clissold D.B., and Bassett S.S. Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335 (1996) 855-859
191. Rubenstein R.C., and Zeitlin P.L. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 278 (2000) C259-C267
192. Rubenstein R.C., and Lyons B.M. Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradation. Am J Physiol Lung Cell Mol Physiol 281 (2001) L43-L51
193. Choo-Kang L.R., and Zeitlin P.L. Induction of HSP70 promotes DeltaF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 281 (2001) L58-L68
194. Rubenstein R.C., Egan M.E., and Zeitlin P.L. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 100 (1997) 2457-2465
195. Rubenstein R.C., and Zeitlin P.L. A pilot clinical trial of oral sodium 4-phenylbutyrate (buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 157 (1998) 484-490
196. Zeitlin P.L., Ener-West M., Rubenstein R.C., Boyle M.P., Lee C.K., and Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 6 (2002) 119-126
197. van der Velden LM, Stapelbroek JM, Krieger E, van den Berghe PV, Berger R, Verhulst PM, et al. Folding defects in ATP8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology 2009 sep 4. [Epub ahead of print].
198. Wang L., Dong H., Soroka C.J., Wei N., Boyer J.L., and Hochstrasser M. Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II. Hepatology 48 (2008) 1558-1569
199. Delaunay J.L., Durand-Schneider A.M., Delautier D., Rada A., Gautherot J., Jacquemin E., et al. A missense mutation in ABCB4 gene involved in progressive familial intrahepatic cholestasis type 3 leads to a folding defect that can be rescued by low temperature. Hepatology (2008)
200. Hayashi H., and Sugiyama Y. 4-phenylbutyrate enhances the cell surface expression and the transport capacity of wild-type and mutated bile salt export pumps. Hepatology 45 (2007) 1506-1516
201. Hayashi H., and Sugiyama Y. Short-chain ubiquitination is associated with the degradation rate of a cell-surface-resident bile salt export pump (BSEP/ABCB11). Mol Pharmacol 75 (2009) 143-150
202. Lam P., Pearson C.L., Soroka C.J., Xu S., Mennone A., and Boyer J.L. Levels of plasma membrane expression in progressive and benign mutations of the bile salt export pump (Bsep/Abcb11) correlate with severity of cholestatic diseases. Am J Physiol Cell Physiol 293 (2007) C1709-C1716
203. Nissim-Rafinia M., and Kerem B. Splicing modulation as a modifier of the CFTR function. Prog Mol Subcell Biol 44 (2006) 233-254
204. Aznarez I., Chan E.M., Zielenski J., Blencowe B.J., and Tsui L.C. Characterization of disease-associated mutations affecting an exonic splicing enhancer and two cryptic splice sites in exon 13 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet 12 (2003) 2031-2040
205. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72 (2003) 291-336
206. Nissim-Rafinia M., Aviram M., Randell S.H., Shushi L., Ozeri E., Chiba-Falek O., et al. Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Rep 5 (2004) 1071-1077
207. Madden H.R., Fletcher S., Davis M.R., and Wilton S.D. Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. Hum Mutat 30 (2009) 22-28
208. Mitrpant C., Adams A.M., Meloni P.L., Muntoni F., Fletcher S., and Wilton S.D. Rational design of antisense oligomers to induce dystrophin exon skipping. Mol Ther (2009)
209. Pros E., Fernandez-Rodriguez J., Canet B., Benito L., Sanchez A., Benavides A., et al. Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Hum Mutat 30 (2009) 454-462
210. Salen G., Starc T., Sisk C.M., and Patel S.B. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 130 (2006) 1853-1857
211. Beuers U., Boberg K.M., Chapman R.W., Chazouillères O., Invernizzi P., Jones D.E.J., et al. EASL clinical practice guidelines: management of cholestatic liver diseases. J Hepatol 51 (2009) 237-267